Xeris Biopharma Holdings, Inc. Comparables
Find the most relevant public market comparables for Xeris Biopharma Holdings, Inc., including EV/Revenue and EV/EBITDA multiples to help you make informed investment decisions.
Company Overview
A growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, focusing on endocrinology, neurology, and gastroenterology.
Business Model
Developing and commercializing innovative, ready-to-use therapeutic medicines utilizing proprietary formulation technology platforms (XeriSol and XeriJect).
Target Customers
Patients with chronic endocrine and neurological diseases, including those with severe hypoglycemia, primary periodic paralysis (PPP), and Cushing's syndrome.
Specific Focus
Ready-to-use injectable drug formulations for chronic endocrine and neurological diseases.
Location
Chicago, Illinois
CEO
John Shannon
Industry
Life sciences
Sub Sector
Specialty Pharmaceuticals
3yr Revenue Growth
702%
Website
Public Market Comparables
Below are the key valuation metrics for companies similar to Xeris Biopharma Holdings, Inc. in the Biopharmaceutical sector. These metrics can help you understand how the market values companies with similar business models and growth profiles.
Looking for a comprehensive compset for Xeris Biopharma Holdings, Inc.? Our platform provides detailed analysis of Xeris Biopharma Holdings, Inc.'s competitive landscape, including financial metrics, growth trends, and market positioning. Get access to the full Xeris Biopharma Holdings, Inc. compset by trying our platform today.
EV/Revenue Multiple
Min
0.0x
Median
0.0x
Max
00.0x
Unlock actual values by trying our platform
View Full DetailsEV/EBITDA Multiple
Min
00.0x
Median
00.0x
Max
00.0x
Unlock actual values by trying our platform
View Full Details
Unlock the Full Xeris Biopharma Holdings, Inc. Compset
As a leading player in the Life sciences industry within the Biopharmaceutical sector, Xeris Biopharma Holdings, Inc. operates in the specialized Specialty Pharmaceuticals sub-sector. Understanding how Xeris Biopharma Holdings, Inc. compares to its public market comps is essential for accurate valuation and strategic decision-making.
Our comprehensive analysis includes detailed comparables (compsets) featuring similar companies in the Specialty Pharmaceuticals space, with complete financial metrics, growth trajectories, and competitive positioning insights that go beyond the surface-level data shown above.
Other Interesting Companies
TG Therapeutics, Inc.
Healthcare • Life sciences
TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. They have received FDA approval for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis.
Vytalize Health
Healthcare • Life sciences
Vytalize Health is a risk-bearing provider enablement platform and leading Accountable Care Organization (ACO) that partners with primary care physicians (PCPs) to deliver value-based care, improving patient outcomes and reducing healthcare costs. They offer an all-in-one solution including value-based incentives, smart technology, and a virtual clinic, enabling independent practices to thrive in value-based care arrangements. The company focuses on Medicare patients and works with over 2,500 PCPs across 36 states.
Talkiatry
Healthcare • Life sciences
Talkiatry is a national mental health practice providing in-network psychiatry and therapy via telehealth. It utilizes technology and a human-centered approach to improve access to high-quality mental healthcare, addressing issues of accessibility and affordability.
Get Your Custom Comparable Analysis
Need a more detailed analysis of Xeris Biopharma Holdings, Inc. and its public market comparables? Our platform provides comprehensive valuation metrics, growth analysis, and more.
Try CompsetFinder Free